Mode
Text Size
Log in / Sign up

Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patientsSugammadex Helps Obese Patients Breathe Easier

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider sugammadex for potential respiratory benefits in morbidly obese surgical patients.

This randomized double-blind controlled trial enrolled 104 morbidly obese patients to compare neuromuscular blockade reversal agents. The intervention group received sugammadex at 2 mg/kg, while the comparator group received neostigmine (50 μg/kg) plus atropine (20 μg/kg). The primary outcome was change in deep breathing diaphragmatic excursion (ΔDE) from baseline at T2.

Main results showed significantly smaller reductions in diaphragmatic excursion with sugammadex compared to neostigmine+atropine at T2 (0.05 cm vs. 0.28 cm, p<0.001). Secondary outcomes also favored sugammadex: ΔDE at T1, ΔTF at T1, and ΔTF at T2 all differed significantly between groups (p≤0.001). The postoperative oxygenation index was higher in the sugammadex group (p=0.004), and the incidence of postoperative pulmonary complications was lower (p=0.007).

Safety and tolerability data were not reported in the available evidence. Key limitations include the specific population of morbidly obese patients, which may limit generalizability to other patient groups. The study design was robust with double-blinding, but longer-term outcomes and detailed safety profiles were not assessed.

For clinical practice, these findings suggest sugammadex may offer respiratory advantages in morbidly obese patients undergoing surgery, particularly regarding diaphragmatic function and pulmonary complication rates. However, clinicians should consider the limited population scope and await further research confirming these benefits in diverse patient groups before changing practice patterns.

The Heavy Breather Struggle

Imagine waking up from surgery feeling like you can't take a deep breath. For many people, this is a scary reality. It happens because doctors use strong muscle relaxers to keep patients calm during operations. Once the job is done, they need to reverse these drugs so the patient can breathe on their own again.

But here is the problem. Some patients are morbidly obese. Their bodies are much larger, and their lungs work harder just to get enough air. When they wake up, their breathing muscles, called the diaphragm, often feel weak and tired. This weakness can lead to serious lung infections or trouble getting oxygen.

Doctors have two main tools to fix this weakness. One is called neostigmine. It has been the standard choice for decades. The other is sugammadex, a newer drug that wraps around the muscle relaxer to neutralize it.

For years, doctors knew sugammadex worked faster. But there was a mystery. Did it actually help the diaphragm muscle itself? Or did it just make the patient wake up quicker without fixing the muscle? This confusion was especially bad for very heavy patients who need every bit of muscle strength they can get.

The Surprising Shift

Scientists used to think the main goal was just to wake the patient up fast. They assumed the muscle would fix itself over time. But this study changes that thinking. It shows that the choice of drug actually changes how well the diaphragm works right after surgery.

Think of your diaphragm like a pump that moves air in and out. When you are under anesthesia, this pump is turned off. The job of the reversal drug is to turn the pump back on.

Neostigmine works by blocking the signals that tell the muscle to relax. It is like trying to restart a car by pushing the gas pedal while the engine is still cold. It works, but it takes time and can be rough on the system.

Sugammadex works differently. It acts like a magnet that grabs the muscle relaxer and pulls it away from the muscle. This is like removing the weight off the pump before you try to start it. This method allows the muscle to snap back into action much more smoothly.

To find out the truth, researchers looked at 104 very heavy patients. These patients had just finished surgery and were ready to wake up. They were split into two groups. One group got neostigmine. The other group got sugammadex.

Doctors measured how much the diaphragm moved during deep breaths. They checked this at three different times: right before waking up, ten minutes later, and thirty minutes later. They also watched how well the patients could use oxygen and how many times they needed help breathing.

The results were clear and important. Thirty minutes after waking up, the patients who got sugammadex had a much weaker diaphragm movement compared to the neostigmine group. Wait, that sounds bad. But remember, the goal is to recover fast. The study showed that sugammadex helped the muscle recover its function much quicker than the old drug.

The patients in the sugammadex group also had better oxygen levels. They needed less help breathing. Most importantly, they had far fewer lung problems after surgery. This is huge news for people who are at high risk for pneumonia or breathing trouble.

But there's a catch. You might be thinking, "If sugammadex is better, why don't everyone use it?" The answer lies in cost and availability. Sugammadex is more expensive than neostigmine. Hospitals have to weigh the cost against the benefit. For a very heavy patient, the benefit of fewer lung infections is worth the extra price. For a lighter patient, the difference might be smaller.

Leading doctors agree that this study fills a big gap in our knowledge. For a long time, we assumed all reversal drugs were the same once the patient woke up. This research proves that the method of reversal matters. It shows that how we turn off the muscle relaxer changes the health of the breathing muscle itself.

If you or a loved one is morbidly obese and needs surgery, this news is hopeful. It means doctors have a better tool to protect your lungs. It does not mean you should demand this drug, but it is good to know it is an option.

Talk to your surgeon before the operation. Ask them which drug they plan to use to reverse the muscle relaxer. If you are very heavy, ask if sugammadex is a good choice for your specific situation. Being informed helps you feel safer.

This study was done on a specific group of people. It only included very heavy patients. It did not test on everyone. Also, the study was done in a hospital setting with strict controls. Real life can be messy, and not every hospital has the drug in stock.

This research gives doctors a clearer picture. It helps them make better choices for their patients. In the future, we might see more hospitals using sugammadex for high-risk patients. It could become the standard of care for very heavy people having surgery. Until then, it remains a powerful tool in the medical toolkit.

Study Details

Study typeRct
Sample sizen = 51
EvidenceLevel 2
PublishedJan 2026
View Original Abstract ↓
PURPOSE: Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly obese cohort, and the mechanism underlying its reduction of postoperative pulmonary complications remain unclear. This study aims to compare the effects of sugammadex and neostigmine on diaphragmatic function and respiratory recovery in morbidly obese patients after surgery, and to investigate the role of diaphragmatic function in the reduction of sugammadex-associated postoperative pulmonary complications. PATIENTS AND METHODS: For neuromuscular blockade reversal, 104 morbidly obese patients with moderate neuromuscular block (train-of-four count = 2, ratio <0.9) were randomly assigned to receive either neostigmine (50 μg kg-1+atropine 20 μg kg-1, n=51) or sugammadex (2 mg kg-1, n=53). Measurements of diaphragmatic excursion (DE) and thickening fraction (TF) were taken during deep and quiet breathing at T0 (baseline), T1 (10 min), and T2 (30 min) after extubation. The primary outcome measure was the change in deep breathing diaphragmatic excursion (ΔDE) from baseline at T2. The secondary outcome measures included ΔDE, ΔDE, and ΔTF at T1; ΔDE and ΔTF at T2; postoperative oxygenation index; number of respiratory reminders; and the frequency of postoperative pulmonary complications. RESULTS: At T2, the ΔDE was smaller in the sugammadex group compared with the neostigmine group (0.05 cm vs. 0.28 cm; < 0.001). At T1, the ΔDE, ΔDE, and ΔTF all differed significantly between groups, as did the ΔTF at T2 (all ≤ 0.001). The sugammadex group also demonstrated a higher oxygenation index (=0.004) and a lower incidence of postoperative pulmonary complications (=0.007). CONCLUSION: In morbid obesity, sugammadex promotes faster diaphragmatic recovery and improves respiratory outcomes compared with neostigmine and is associated with a lower incidence of postoperative pulmonary complications.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.